I have an impersonator. Please help me in reporting
@CaptnKirk31
. For future reference, know that I would never DM anyone about making an investment in anything. Thanks for your help and to those who flagged this for me.
Bonitas is Short Harrow Health ($HROW). Harrow sells prescription eye drugs in the United States. U.S. DOJ Investigation, FDA Hurricane: Regulatory Meeting, Recall, Inspection, Warning Letter; Weak Novartis Drug Sales (1/x)
And $HROW does not burn cash from operations and does not rely on external financing for survival. It may not be totally visible because you have to read through filings and get a little creative but that's where the opportunity is.
I was lucky enough to be at this game. This was the most exciting half inning of baseball I’ve ever witnessed. And this led to the Victorino grand slam a few batters later. All while the financial world was collapsing around us
Google searches for "day trading" and "buying options" going off the charts. Just like pot stocks and bitcoin. People thinking they'll get rich over night. Nothing more than pump and dumps. There really are suckers born every day
We’ve paid $2.6B in corporate taxes since 2016. We pay every penny we owe. Congress designed tax laws to encourage companies to reinvest in the American economy. We have. $200B in investments since 2011 & 300K US jobs. Assume VP Biden’s complaint is w/ the tax code, not Amazon.
Robinhood fined $1.25MM for allowing four broker dealers to frontrun orderflow. The CEO of one of Robinhood's brokers just bought a quarter billion dollar penthouse in NYC
and Harrow has cooperated with the FDA to assure that all allegations in the warning letters and 483s have been addressed.
The recall was due to that batch of the product not being potent enough.
5. Radley, Mayfield, and Stowe were exited due to focusing the company exclusively on ophthalmology, which these were not. Surface and Melt were "written down" due to equity method of accounting. Clinical stage pharmaceutical companies have losses.
3. $HROW acquired these drugs from Novartis at less than 4x ebitda. This is the "Fab Five" not the spin-offs you refer to. This price does not imply any growth needed for the acquisition to be successful for Harrow. Novartis was exiting this business and pulled back on marketing
reimbursement. Dexycu revenues were immaterial to Harrow.
2. Everything prior to 2019 has been discussed by the company in filings and in my opinion is not meaningful to the current state of the company.
Inspections are a normal course of business. FDA form 483 is an opinion
leaving these drugs in an orphan state. Harrow knows this and plans to breathe new life into these drugs by implementing them into their platform.
4. 4.5million cataract surgeries per year and growing. There is a market here for Iheezo to compete in.
1. Harrow as of now is not under investigation, Eyepoint Pharmaceuticals received the subpoena. Harrow was not in full control of marketing until 2022. As of Jan 1, 2023 the sales agreement with Eyepoint was terminated due to Dexycu no longer qualifying as a separate